| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 282, Issue 7, 4765-4771, February 16, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana 46556
Received for publication, October 11, 2006 , and in revised form, November 20, 2006.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
The p53 tumor suppressor exerts antiproliferative effects, including growth arrest and apoptosis, in response to various types of stress (3). Mutations within the p53 gene have been documented in more than half of all human tumors, and even in cells that retain wild-type p53 other defects in the p53 pathway play an important role in tumorigenesis (4). Most of the tumor-suppressive functions of p53 have been attributed to the ability of the protein to act as a transcriptional modulator of downstream target genes, particularly those involved in cell cycle arrest and apoptosis (5, 6), although the precise mechanism by which p53 is activated by cellular stress is not fully understood. It is generally accepted that post-translational modifications of p53, including phosphorylation and acetylation, play important roles in the stabilization and activation of p53 (7). Several lysine (Lys) residues in the C-terminal domain of p53 can be acetylated, including Lys-320, Lys-373, and Lys-382 (8, 9). Because these sites are also the target for mdm2-mediated ubiquitination, acetylation of these sites leads to an increase in the steady state level of p53. Thus HDIs that prevent the deacetylation of the protein effectively stabilize the acetylated isoforms of p53 by blocking mdm2-mediated ubiquitination (10). In addition to increasing the steady state level of the p53, acetylation stimulates the sequence-specific binding of p53 and its transcriptional activation of downstream target genes such as p21 (11, 12); however, the identities of the specific HATs and HDAC enzymes that modulate the acetylation status of p53 protein and the functions of the acetylated isoforms in transcriptional regulation are still largely unknown. We have previously shown that two HDIs, CG-1521 (7-phenyl-2,4,6-hepta-trienoic hydroxamic acid) and TSA, stabilize acetylation of p53 at Lys-373 and Lys-382, respectively, in LNCaP prostate cancer cells. In these cells, acetylation of Lys-373 p53 correlates with both cell cycle arrest and cell death, whereas acetylation of Lys-382 p53 only correlates with cell cycle arrest (13). This suggests that the selective stabilization of the acetylated isoforms by individual HDIs modulates the expression of different subsets of genes.
In this report we show that site-specific stabilization of acetylated p53 results in the formation of mutually exclusive transcriptional complexes that are differentially recruited to the p53 response elements (p53REs) in the promoter of the p21 gene, leading to profoundly different effects on the assembly of the basal transcriptional apparatus. These data provide a mechanistic explanation for the selective effects of these two HDIs and suggest that the design of selective HDIs will provide exceptional opportunities for tailored therapies based on the knowledge of which HDACs are active in target cells.
|
EXPERIMENTAL PROCEDURES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Drug Treatments—LNCaP cells were treated with 7.5 µM CG-1521 (Errant Gene Therapeutics, LLC, Chicago, IL) or 5 µM TSA (T8552; Sigma) dissolved in Me2SO.
Nuclear Fractionation—Cells were scraped, pelleted by centrifugation at 1500 rpm for 3 min at 4 °C, resuspended in ice-cold wash buffer (25 mM Tris, pH 7.5, 250 mM sucrose, 2.5 mM MgCl2, 10 mM benzamidine, 10 mM NaF, 1 mM sodium vanadate, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 µg/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride), and pelleted at 1500 rpm for 3 min at 4 °C. Pellets were resuspended with three volumes of Buffer A (20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 250 mM sucrose, 1 mM sodium vanadate, 1 mM dithiothreitol, 25 µg/ml leupeptin, 25 µg/ml aprotinin, 2.5 µg/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride, 10 mM benzamidine, and 20 mM NaF) and lysed with a Dounce homogenizer. Homogenates were centrifuged twice at 1500 rpm for 6 min at 4 °C, and the nuclear pellets were resuspended in Buffer A, sonicated for 20 s, and stored at -20 °C.
Co-immunoprecipitation Assay—Co-immunoprecipitation of Ac-Lys-373 p53 and Ac-Lys-382 p53 was performed with nuclear fraction of LNCaP cells treated with 7.5 µM CG-1521 and 5 µM TSA (standardized in our previous work) (13) for 8 h separately and in combination, along with untreated nuclear fractions using the ProFoundTM mammalian co-immunoprecipitation kit (Pierce Biotech).
Western Blot Analysis—20 µl of the eluant from the co-immunoprecipitation assay were solubilized in loading buffer containing 5% 1 M dithiothreitol, separated by SDS-PAGE, and transferred to nitrocellulose. Transfer of proteins was confirmed by Ponceau-S staining (BDH, Dorset, England). Immunoblots were incubated overnight at 4 °C with primary antibodies, including rabbit anti-Ac-Lys-373 p53 (06-916; Upstate%20Biotechnology">Upstate Biotechnology, Lake Placid, NY), rabbit anti-Ac-Lys-382 p53 (01-010-179M; American Proteomics, Carlsbad, CA), mouse anti-androgen receptor (Clone G122-25, 554224; BD Biosciences), mouse anti-acetyl-lysine (Clone 4G12, 05-515: Upstate%20Biotechnology">Upstate Biotechnology), rabbit anti-p300 (C-20, SC-585; Santa Cruz Biotechnology), mouse anti-CBP (C-1, SC-7300; Santa Cruz Biotechnology), goat anti-Brm (N-19, SC-6450; Santa Cruz Biotechnology), rabbit anti-BRG1 (H-88, SC-10768; Santa Cruz Biotechnology), goat anti-HNF-3
/
(Foxa1) (C-20, SC-6553; Santa Cruz Biotechnology), goat anti-Foxm1 (C-20, SC-26688; Santa Cruz Biotechnology), goat anti-Pol II (C-18, SC-5943; Santa Cruz Biotechnology), rabbit anti-TFIIH p62 (Q-19, SC-292; Santa Cruz Biotechnology), or goat anti-Ran (C-20, SC-1156; Santa Cruz Biotechnology) diluted in blocking solution (5% milk in 0.05% phosphate-buffered saline-Tween). Specific antibody binding was detected by goat anti-mouse (170-6516; Bio-Rad), goat anti-rabbit (170-6515; Bio-Rad), or donkey anti-goat (SC-2020; Santa Cruz Biotechnology) IgG antibody conjugated with horseradish peroxidase diluted 1:5000 or 1:10000 in blocking solution and autoradiographed with enhanced chemiluminescence (Pierce). The membranes were stripped with Western Re-ProbeTM buffer (786-119; Geno Technology, St. Louis, MO).
Reverse Transcription PCR—Total RNA was extracted from LNCaP cells untreated and treated with 7.5 µM CG-1521 or 5 µM TSA for the indicated times (0–72 h) using the Qiagen RNeasyTM Midi kit (75144; Qiagen, Valencia, CA). Reverse transcription PCR reactions were performed with 1.5 µg of RNA samples using Taqman® reverse transcription reagents (N8080234; Applied Biosystems, Foster City, CA). The reaction mixture was incubated for 10 min at 25 °C, 1 h at 37 °C, and 5 min at 95 °C and kept at 4 °C until further analysis. Each sample was replicated three times from three independent sets of RNA preparations.
Quantitative Real-time PCR—Real-time SYBR Green probes for p21 gene were designed using Primer ExpressTM 1.5 (Applied Biosystems) and synthesized by Integrated DNA Technologies (Coralville, IA). p21 forward 5'-CCT AAT CCG CCC ACA GGA A-3' and p21 reverse 5'-ACC TCC GGG AGA GAG GAA AA-3'. SYBR Green reactions were performed using the SYBR® Green PCR Master Mix (4309155; Applied Biosystems). SYBR Green reactions were performed using an ABI PrismTM 7700 Sequence Detector (Applied Biosystems) and incubated for 2 min at 50 °C, 10 min at 95 °C, 15 s at 95 °C, and 1 min at 60 °C for 50 cycles. Relative expression levels of p21 in real time were analyzed using the 2-
CT method (14) and presented as ratio to the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase. Each sample was replicated twice from three independent sets of RNA preparations. Results are tabulated as mean ± S.E. of three independent experiments. Means were considered statistically significant (*) at p < 0.05.
Chromatin Immunoprecipitation Assay—LNCaP cells were plated at a density of 1 x 106 cells/dish in 20-mm dishes (08772E; Fisher Scientific), treated with 7.5 µM CG-1521 or 5 µM TSA, and harvested after 8 h of treatment. Cells were scraped from the dish and collected by centrifugation at 1200 rpm for 5 min at 4 °C. The cells were then cross-linked with a 1% formaldehyde solution for 10 min at 37 °C. Cross-linking was stopped by addition of glycine to 125 mM final concentration for 5 min at room temperature. Cells were washed twice with ice-cold phosphate-buffered saline and once with ice-cold phosphate-buffered saline supplemented with 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, and 1 µg/ml pepstatin A. Cells were then pelleted at 12,000 rpm for 5 min at 4 °C. Chromatin immunoprecipitation was performed using the chromatin immunoprecipitation (ChIP) assay kit (17-295; Upstate%20Biotechnology">Upstate Biotechnology). 1.5% of the diluted sample was set aside as the input DNA. For immunoprecipitation, the sample was precleared for 30 min at 4 °C with 75 µl of salmon sperm DNA/protein A-agarose-50% slurry (16-157C; Upstate%20Biotechnology">Upstate Biotechnology) before addition of indicated antibodies. The antibodies used for the immunoprecipitation assay were: anti-total p53 mouse monoclonal (05-224; Upstate%20Biotechnology">Upstate Biotechnology), anti-Ac-Lys-373 p53 rabbit polyclonal (06-916; Upstate%20Biotechnology">Upstate Biotechnology), anti-Ac-Lys-382 p53 rabbit polyclonal (01-010-179M; American Proteomics, Carlsbad, CA), anti-p300 mouse monoclonal (554215; BD Biosciences), anti-CBP rabbit polyclonal (SC-369; Santa Cruz Biotechnology), anti-HDAC1 mouse monoclonal (05-614; Upstate%20Biotechnology">Upstate Biotechnology), anti-HDAC2 rabbit polyclonal (07-222; Upstate%20Biotechnology">Upstate Biotechnology), anti-Pol II (H-224) rabbit polyclonal (SC-9001; Santa Cruz Biotechnology), anti-TBP mouse monoclonal (AB818; Abcam Inc., Cambridge, MA), or anti-TFIIH (Q-19) rabbit polyclonal (SC-292; Santa Cruz Biotechnology). 2 µg of each antibody were added to the reactions and incubated overnight at 4 °C. An isotype control was performed in the presence of the respective IgGs. Collection of the antibody-histone complex was performed by addition of 60 µl of salmon sperm DNA/protein A-agarose-50% slurry for 1 h at 4 °C. Agarose beads containing the antibody-histone complex were collected by gentle centrifugation (3000 x g for 1 min at 4 °C) and washed several times, and immunocomplexes were eluted twice for 15 min each at room temperature with 1% SDS and 0.1 M NaHCO3. Cross-linking was reversed by addition of 20 µl of 5 M NaCl (20-159; Upstate%20Biotechnology">Upstate Biotechnology) to 500 µl of eluates and incubating for 4 h at 65 °C. DNA was purified by phenol-chloroform extraction, and 1 µg of purified DNA was used as a template in PCR reactions using primers for -1.3 kb p53RE, -2.4 kb p53RE, and p21 basal promoter (15) and -5 kb control region in the p21 promoter (16) (supplemental data). All reactions were incubated initially for 5 min at 95 °C and then for 45 s at 95 °C, 1 min at 61.5 °C (65.5 °C for basal promoter), and 1 min at 72 °C for 35 cycles, with the final extension for 7 min at 72 °C. Amplification products were electrophoresed in 2% agarose gels and visualized by ethidium bromide. 1.5% of total input DNA was subjected to PCR (Input). PCR products for -1.3 and -2.4 kb p53REs, -5 kb control region, and p21 basal promoter were 197, 282, 500, and 214 bp, respectively, and were quantified by densitometry using Scion Image software (Scion Corp, Frederick, MD). Percentage of immunoprecipitated DNA was calculated by comparison to input signals and plotted as bar graphs with statistical significance (*) measured at p < 0.01. Data represent the average of three independent sets of experiments.
Statistical Analysis—All data are expressed as the mean ± S.E. One-way analysis of variance was used to assess statistical significance between means. Differences between means were considered significant when p < 0.05 using the Bonferroni post-test. All statistical analyses were performed with the GraphPad Instat software (Intuitive Software for Science, San Diego, CA).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
|
|
|
Acetylated p53 Isoforms Assemble Different Cofactor Complexes on the p21 Promoter—We have used ChIP to investigate the assembly of transcription factors on the p21 promoter after treatment of LNCaP cells with CG-1521 and TSA. The p21 promoter contains two well characterized p53REs at -2.4 and -1.3 kb upstream of the transcription start site (15) (Fig. 3A). The relative enrichment of specific transcription factors at each site after treatment with CG-1521 and TSA was determined after chromatin immunoprecipitation using PCR primers flanking these two sites. Prior to treatment, p53 is associated mainly with the -2.4 kb site. Treatment with CG-1521 significantly increases the binding of Ac-Lys-373 p53 at both p53Res, but most significantly at the -1.3 kb site. In contrast, TSA slightly increases the binding of Ac-Lys-382 p53 to the -2.4 kb site and to a lesser extent to the -1.3 kb site (Fig. 3B).
|
|
As shown in Fig. 4C, these complexes have markedly different abilities to recruit components of the basal transcription apparatus, namely TATA box-binding protein (TBP), RNA polymerase II, and TFIIH. Prior to treatment, RNA Pol II and TBP already associate with the basal promoter of the p21 gene but TFIIH is not associated with the complex. After treatment with CG-1521, there is a substantial increase in binding of TBP to the basal promoter and TFIIH is recruited to the basal promoter, coinciding with a decrease in RNA Pol II occupancy, which is consistent with the initiation of transcription. In contrast, after treatment with TSA, neither TBP nor TFIIH is associated with the basal promoter and binding of RNA Pol II to the basal promoter is significantly reduced. This most likely reflects the decreased occupancy of the TATA box by TBP.
These data indicate that a preassembled initiation complex containing a paused RNA Pol II is present at the p21 promoter. Binding of Ac-Lys-373 p53 and its associated cofactors (including p300 and HDAC1), to the p53REs leads to the recruitment of TFIIH to the basal transcriptional complex and activation of RNA Pol II. In contrast, even though Ac-Lys-382 p53 and its associated cofactors (CBP and HDAC2) bind to the p53REs, the complexes do not initiate the assembly of RNA Pol II on the basal promoter (Fig. 5).
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
LNCaP cells express several HATs, including P/CAF, p300, CBP, and Tip60 (26, 27), as well as the zinc-dependent class I and II HDACs 1, 2, 3, and 4 (13, 28) and the NAD+-dependent class III enzyme Sirt1 (29). Thus, the effect of individual HDIs on these cells represents a composite effect on the biology of cells that have similar HATs and HDACs. Comparison of the effects of CG-1521 and TSA, two hydroxamic acid-based inhibitors, has shown that despite the similarity in structure these compounds have very different effects on LNCaP cells. CG-1521 induces G2/M arrest and apoptosis, whereas TSA induces G1/S arrest but does not induce apoptosis (13). These two compounds induce markedly different effects on the acetylation status of p53: CG-1521 stabilizes Ac-Lys-373 p53 whereas TSA stabilizes Ac-Lys-382 p53. Our previous studies have shown that Lys-320 is constitutively acetylated in LNCaP cells and the acetylation at Lys-320 is not affected by CG-1521 or TSA (13). Acetylation of p53 at either Lys-373 or Lys-382 blocks the mdm2-mediated ubiquitinylation of p53, which increases the steady state level of the acetylated proteins. However, as the data presented here show, the differences in acetylation status are not due solely to the increased steady state levels of p53. The ability of the different acetylated isoforms to recruit distinct co-activator complexes to the p21 promoter is the major factor in determining the downstream events associated with these HDIs. Ac-Lys-373 p53 recruits p300, forkhead transcription factors, the androgen receptor, and Brg-1. When assembled on the p53REs in the p21 promoter, this complex induces the assembly of TBP, RNA Pol II, and TFIIH on the basal promoter and initiates p21 transcription. In contrast, Ac-Lys-382 p53 recruits CBP and Brm-1 to the p53REs in the proximal p21 promoter, but this complex does not recruit TBP, RNA Pol II, or TFIIH to the basal promoter, suggesting that Ac-Lys-382 p53 promotes the assembly of a non-functional complex on the p21 promoter. Thus, in addition to the general effects on steady state mRNA levels, these HDIs have specific effects on the assembly of transcription complexes, at least on the p21 promoter. These data lend support to the concept proposed by Knights et al. (30) that distinct p53 acetylation cassettes influence gene expression. Genome-wide array suggests that, in addition to p21, CG-1521 modulates the expression of 233 genes in total, of which a highly circumscribed group of 40 genes are involved in cell cycle, cell proliferation, or cell death. In contrast, TSA modulates over 1700 genes, 1400 of which are down-regulated. Of these, 150 genes are associated with cell cycle, cell proliferation, or apoptosis as described by Gene Ontology (GeneSpring GX 7.2 software; Agilent Technologies).4 This extensive transrepression of gene expression has also been noted in the p53-mediated response to hypoxia (31). Although it is tempting to attribute the dramatic difference in the effects of CG-1521 and TSA solely to the site of acetylation in the C-terminal domain of p53, Ac-Lys-373 p53 is also selectively phosphorylated in the N-terminal domain at Ser-15. Based on the available evidence it is not possible to determine whether one or both post-translational modifications are necessary for the assembly of the active transcription complex on the p21 promoter. Nevertheless, these data suggest that the effects of CG-1521 and TSA are attributable, at least in part, to the selective effects of the HDIs on HDAC activities that lead to differences in the p53-mediated induction of p21 transcription. However, because HDACs have multiple target proteins and the specificity of the HDIs has not been precisely delineated, it is not possible to exclude the possibility that the overall biological effect of these compounds, particularly the global effects of TSA, is due to the acetylation of other transcription factors.
In summary, although the interactions between HATs, HDACs, and HDIs are clearly complex and not fully understood, the data presented here demonstrate that selective inhibition of HDACs is possible and can lead to significant changes in gene expression through the acetylation of transcription factors such as p53. This holds out promise that tailored therapies based on a more refined knowledge of the cellular HDAC composition will be possible.
|
FOOTNOTES |
|---|
The on-line version of this article (available at http://www.jbc.org) contains supplemental Table S1.
1 Supported by a Pat Girondi fellowship in molecular medicine.
2 To whom correspondence should be addressed. Tel.: 574-631-3372; Fax: 574-631-7413; E-mail: tenniswood.1{at}nd.edu.
3 The abbreviations used are: HDAC, histone deacetylase; HAT, histone acetyltransferase; HDI, HDAC inhibitor; TSA, trichostatin A; p53RE, p53 response element; ChIP, chromatin immunoprecipitation; POL II, polymerase II; TBP, TATA box-binding protein; CBP, CREB (cAMP-response element-binding protein)-binding protein.
4 S. Roy and M. Tenniswood, unpublished data.
|
ACKNOWLEDGMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  W.-W. Tsai, T. T. Nguyen, Y. Shi, and M. C. Barton p53-Targeted LSD1 Functions in Repression of Chromatin Structure and Transcription In Vivo Mol. Cell. Biol., September 1, 2008; 28(17): 5139 - 5146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Roy, R. Jeffrey, and M. Tenniswood Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells Mol. Cancer Ther., July 1, 2008; 7(7): 1931 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hebner, M. Beglin, and L. A. Laimins Human Papillomavirus E6 Proteins Mediate Resistance to Interferon-Induced Growth Arrest through Inhibition of p53 Acetylation J. Virol., December 1, 2007; 81(23): 12740 - 12747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sayeed, S. D. Konduri, W. Liu, S. Bansal, F. Li, and G. M. Das Estrogen Receptor {alpha} Inhibits p53-Mediated Transcriptional Repression: Implications for the Regulation of Apoptosis Cancer Res., August 15, 2007; 67(16): 7746 - 7755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Scoumanne and X. Chen The Lysine-specific Demethylase 1 Is Required for Cell Proliferation in Both p53-dependent and -independent Manners J. Biol. Chem., May 25, 2007; 282(21): 15471 - 15475. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
